Medical Cannabis and Opioid Management: Substitution Patterns in Canadian Patients
Last Updated: February 2026 | Reading Time: 4 minutes
Opioid use among Canadian veterans and in community harm reduction settings intersects directly with chronic pain management. Two major Canadian studies — one from the federal medical cannabis program, one from a major BCCSU longitudinal cohort — document cannabis substitution for opioids at rates that are too significant to treat as incidental. This article reviews what the evidence shows and what it means for clinicians managing patients with concurrent pain and opioid use.
The Authorized Patient Data
The most comprehensive picture of cannabis substitution for opioids among authorized Canadian patients comes from Lucas, Baron & Jikomes (2019), a cross-sectional survey of 2,032 patients in Canada’s federal medical cannabis program, published in Harm Reduction Journal (16(1): 9).
The headline finding for opioid management: 69.1% of authorized patients reported substituting cannabis for prescription medications. Within that group, opioids accounted for 35.3% of all prescription drug substitution mentions, the largest single medication category, with antidepressants second at 21.5%. Of the 610 mentions of specific opioid medications, patients reported total cessation in 59.3% of cases. Chronic pain was the primary condition driving authorization, and patients managing pain were among the most likely to report substitution.
These are patient-reported substitution patterns, not pharmacologically verified reductions in prescribed doses. What they reflect is self-reported behaviour change among people who obtained medical authorization and had access to a regulated supply. The clinical significance is in the direction and magnitude: across a cohort of more than 2,000 Canadian authorized patients, the majority reported shifting their prescription medication use following cannabis authorization.
The same study found that 44.5% of authorized patients reported substituting cannabis for alcohol — relevant for patients managing pain alongside alcohol use, a common co-occurrence in chronic pain populations.
Community Cohort Evidence: The BCCSU Data
A 2023 cross-sectional study by Reddon, Lake, Socias, Hayashi, DeBeck, Walsh & Milloy, published in the International Journal of Drug Policy (PMC10817207), examined opioid use and cannabis access in a community sample of 205 opioid users in Vancouver. Among them, 57.6% reported decreasing opioid use through cannabis.
The study’s primary finding was that using cannabis specifically to manage opioid cravings was significantly associated with self-assessed opioid reduction in adjusted analysis (aOR=2.13, p=0.032), as was daily cannabis use (aOR=3.87, p=0.028). The operative variable is intentional, consistent use rather than incidental or intermittent access. The paper names High Hopes Foundation among the free cannabis distribution programs accessible to participants, and descriptively notes that participants reporting both craving management and opioid reduction were more likely to access such programs, though free program access was not an independent statistically significant predictor in the adjusted model.
The implication for clinical practice is that authorization alone may be insufficient if cost or access barriers prevent consistent daily use. Coverage pathways that remove the financial barrier to consistent use matter clinically, not just financially.
What the Combined Evidence Suggests for Practice
The Lucas et al. and Reddon et al. findings converge on two points. First, cannabis substitution for opioids is not rare in Canadian patient populations — it is occurring at majority rates in both authorized federal program patients and in community harm reduction settings. Second, the consistent pattern in both studies is that intentional, daily use with access to a reliable supply produces more reliable substitution outcomes than informal or intermittent access.
For clinicians managing patients with chronic pain who are on opioid therapy, the evidence does not support replacing opioids with cannabis as a clinical protocol. What it does support is treating cannabis authorization as a relevant variable in the clinical picture for patients already using cannabis informally, patients whose opioid dose has been difficult to taper, and patients who have requested cannabis as part of their pain management.
Opioid Substitution and the Veteran Population
Veterans with chronic pain have elevated rates of opioid prescribing relative to the general population, and opioid-related harms in this population are well-documented in the Canadian literature. The Lucas et al. (2019) cohort was drawn from Canada’s federal authorized patient program, the same regulatory framework governing licensed producers operating under Health Canada, making the substitution rates directly relevant to the veteran population.
For veterans already on opioid therapy, cannabis authorization through a licensed producer provides a consistent, quality-controlled supply that is reimbursable through VAC and Medavie Blue Cross for eligible patients. The authorization decision is the clinician’s; the supply, coverage, and administrative management are handled through the licensed producer relationship.
This article summarizes published peer-reviewed research for informational purposes. It is intended for healthcare professionals and does not constitute clinical guidelines. Clinicians should exercise professional judgment and consult current guidelines when making prescribing decisions.
References
- Lucas, Baron & Jikomes (2019). Harm Reduction Journal, 16(1): 9. DOI: 10.1186/s12954-019-0278-6
- Reddon, Lake, Socias, Hayashi, DeBeck, Walsh & Milloy (2023). International Journal of Drug Policy. PMC10817207